NCT01082289

Digoxin Drug-Drug Interaction With Lurasidone HCl

A Phase 1, Open-Label, Drug-Drug Interaction Study to Determine the Effect of Repeated Dose Lurasidone 120 mg Administration on the Pharmacokinetics of Orally Administered Digoxin 0.25 mg in Patients With Schizophrenia or Schizoaffective Disorder.

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Sumitomo Pharma America, Inc. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The objective of this study is to evaluate the pharmacokinetic profile of digoxin when administered alone and when administered with repeated dose of lurasidone 120mg.

Conditions

• Schizophrenia

Interventions

Type	Name	Description
DRUG	Lurasidone

Timeline

• Start date: 2008-09-01
• Primary completion: 2008-10-01
• Completion: 2008-10-01
• First posted: 2010-03-08
• Last updated: 2011-09-08

Locations

1 site across 1 country: United States